2018 has already been an impressive year for biotech M&A mega deals - GSK teaming up with 23andMe to boost R&D, Celgene's $9 billion acquisition of Juno Therapeutics and Sanofi's acquisitions of Bioverativ Inc & Ablynx. But what is the secret to these successful biotech and pharma alliances? 

PatSnap welcomed three industry experts for a live panel discussion around investment and M&A matchmaking in pharma and biotech. We also explored: 

  • What's needed for small companies to attract large organisations to consider acquiring them?
  • The main drivers and barriers when it comes to investment in pharma and biotech companies
  • Whether there really is such a thing as the 'perfect' acquisition target

Meet our expert panel: 

  • James West, Vice President at Results Healthcare 
  • Jurgen Vollrath, President at Exponential Technology Counsel
  • Martin Gouldstone, CBO at BenevolentAI